Announcements Trials
Browse Landscape

Status

Approved for marketing 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 99Observational 2Expanded_access 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Head and Neck Neoplasms 1

Interventions

nilotinib 5dabrafenib 4Nivolumab 4Afatinib 4trametinib 3regorafenib 3midostaurin 3elotuzumab 3TIC10 compound 3Sunitinib 3Prednisone 3Capecitabine 3Abiraterone Acetate 33-Iodobenzylguanidine 3venetoclax 2tucatinib 2tempol 2tazemetostat 2talquetamab 2talimogene laherparepvec 2ruxolitinib 2pomalidomide 2olaparib 2niraparib 2leronlimab 2lenvatinib 2ibrutinib 2gilteritinib 2ceritinib 2brexucabtagene autoleucel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × Gefitinib × Clear all
NCT00684385 2019-03-14

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

AstraZeneca

Approved for marketing
Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

NCT00683306 2018-09-13

Open Label Extension Study With Gefitinib (IRESSAâ„¢) for Completing Trial Patients Who May Benefit From Further Treatment

AstraZeneca

Approved for marketing
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡